Cantor Fitzgerald Brokers Boost Earnings Estimates for SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Soleno Therapeutics in a research report issued on Wednesday, July 16th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($2.10) per share for the year, up from their prior estimate of ($3.44). Cantor Fitzgerald currently has a “Overweight” rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics’ FY2026 earnings at $0.84 EPS.

A number of other equities analysts also recently commented on SLNO. Laidlaw boosted their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. Guggenheim upped their price objective on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Stifel Nicolaus upped their price objective on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, March 28th. TD Cowen began coverage on shares of Soleno Therapeutics in a research note on Monday, June 23rd. They issued a “buy” rating and a $110.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Soleno Therapeutics in a research note on Tuesday, April 15th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $108.70.

Soleno Therapeutics Stock Performance

Shares of SLNO stock opened at $87.20 on Friday. The company has a current ratio of 19.64, a quick ratio of 19.64 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average price of $79.81 and a 200 day moving average price of $64.04. The company has a market cap of $4.39 billion, a P/E ratio of -18.87 and a beta of -2.63. Soleno Therapeutics has a 12 month low of $41.50 and a 12 month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.19.

Institutional Investors Weigh In On Soleno Therapeutics

Several hedge funds have recently made changes to their positions in SLNO. AlphaQuest LLC boosted its stake in shares of Soleno Therapeutics by 1,154.4% during the fourth quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after buying an additional 658 shares during the period. Springhill Fund Asset Management HK Co Ltd acquired a new stake in shares of Soleno Therapeutics during the fourth quarter worth about $81,000. Summit Investment Advisors Inc. boosted its stake in shares of Soleno Therapeutics by 24.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company’s stock worth $120,000 after buying an additional 522 shares during the period. Quarry LP acquired a new stake in shares of Soleno Therapeutics during the first quarter worth about $121,000. Finally, Avanza Fonder AB boosted its stake in shares of Soleno Therapeutics by 14.8% during the first quarter. Avanza Fonder AB now owns 1,951 shares of the company’s stock worth $144,000 after buying an additional 251 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

Insider Buying and Selling at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the sale, the insider owned 13,206 shares in the company, valued at approximately $1,092,928.56. This represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.40% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.